Vinorelbine (trade name Navelbine) is a semi-synthetic vinca-alkaloid with a broad spectrum of anti-tumour activity. Vinorelbine is a mitotic spindle poison that impairs chromosomal segregation during mitosis. It blocks cells at G2/M. Microtubules (derived from polymers of tubulin) are the principal target of vinorelbine. Vinorelbine was developed by Pierre Fabre under licence from the CNRS in France. NAVELBINE (vinorelbine tartrate) as a single agent or in combination is indicated for the first line treatment of non small cell lung cancer and advanced breast cancer.

There is no available sources on the medical use of platinum iodide. The salt is insoluble.

Vinblastine is a Vinca alkaloid obtained from the Madagascar periwinkle plant. Vinca alkaloids were found out in the 1950's by Canadian scientists, Robert Noble and Charles Beer for the first time. Medicinal applications of this plant lead to the monitoring of these compounds for their hypoglycemic activity, which is of little importance compared to their cytotoxic effects. They have been used to treat diabetes, high blood pressure and the drugs have even been used as disinfectants. Nevertheless, the vinca alkaloids are so important for being cancer fighters. The mechanism of action of vinblastine sulfate has been related to the inhibition of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Vinblastine is an antineoplastic agent used to treat Hodgkin's disease, non-Hodgkin's lymphomas, mycosis fungoides, cancer of the testis, Kaposi's sarcoma, Letterer-Siwe disease, as well as other cancers.

Vinrosidine (leurosidine) is a leurosine-like alkaloid originally isolated from Vinca rosea Linn. Vinrosidine exerts antitumor activity in animal models.

Salcaprozate sodium (SNAC), an oral absorption promoter that was discovered as part of a screen to identify carrier-based permeation enhancers (Pes) that could “chaperone” poorly permeable payloads across the intestine. Its potential therapeutic application as a delivery agent was tested in many formats: taste-masked liquids, tablets, and soft gelatin capsules. SNAC is the most extensively tested carrier and the only PE approved in an oral formulation designed to improve oral bioavailabilities. The mechanism of action of this compound is not clear. However, Novo Nordisk offered a mechanism of action for SNAC in its non-enteric coated tablet of the glucagon-like peptide 1 analog, semaglutide. SNAC formed a complex around the semaglutide in the stomach and caused a transient increase in local pH around the molecule. It is claimed that semaglutide is protected against pepsin by SNAC and that solubility was increased, resulting in an increased concentration-dependent flux of semaglutide across the gastric mucosa, using a transcellular mechanism as the tablet comes in intimate contact with the epithelium. Clinical trials for patients with Type 2 Diabetes have shown that the oral semaglutide co-formulated with 300 mg SNAC could be used for further clinical development.

Vinrosidine (leurosidine) is a leurosine-like alkaloid originally isolated from Vinca rosea Linn. Vinrosidine exerts antitumor activity in animal models.